Therapeutic CD154 antibody for lupus: promise for the future?
Systemic lupus erythematosus (SLE) is a prototypical systemic autoimmune disease characterized by the production of pathogenic autoantibodies. A new study demonstrates that passive antibody specific for the TNF family member, CD154, ameliorates disease by reducing levels of self-reactive antibody in the serum. This study demonstrates a substantial potential for anti-CD154 antibody in the treatment of humoral autoimmunity.
Kelsoe
Garnett
G
Department of Immunology, Duke University, Durham, North Carolina 27710, USA. ghkelsoe@duke.edu
D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D001323:Autoantibodies / Q000276:immunology / Q000378:metabolism; D015551:Autoimmunity / Q000276:immunology; D023201:CD40 Ligand / Q000276:immunology*; D006801:Humans; D007116:Immunization, Passive; D008180:Lupus Erythematosus, Systemic / Q000276:immunology* / Q000628:therapy*
D000911:Antibodies, Monoclonal; D001323:Autoantibodies; D023201:CD40 Ligand